Haleon, the biotech firm, has had a rollercoaster period with shares hitting a new 12-month low and multiple brokering firms altering their stock ratings. Notably,
Barclays downgraded Haleon to 'equal weight,' due to growth concerns, and
Goldman Sachs upgraded the stock predicting expected growth acceleration. Transaction in own shares through Haleon's share buyback program has also been a recurring theme, indicating a strategic move to strengthen their financial and market position. However, Haleon faced criticism for trimming its organic revenue growth outlook and insiders selling a substantial number of shares. Big firms like Douglas Lane & Associates and Procyon Advisors have cut their holdings in Haleon. Yet, Haleon found buyers in Ascent Group and Millennium Management, with the latter purchasing 3,687,613 shares. Further, Haleon's decision to sell its final stake in consumer healthcare giant Pfizer fetched $3.2B. Importantly, despite some setbacks, Haleon's stocks have shown resiliency with the promise of a turnaround due to a rise based on U.S. recovery expectations.
Haleon Stocks News Analytics from Wed, 15 Jan 2025 08:00:00 GMT to Sat, 20 Sep 2025 21:04:24 GMT -
Rating -7
- Innovation -6
- Information -6
- Rumor -3
